PTSD, Trauma & Stress Disorders

Preclinical mGlu7 negative allosteric modulator ADX71743 disrupts fear-memory reconsolidation.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

Veterans face significant PTSD challenges, with tailored treatments and ongoing research essential for improving their mental health outcomes.

Women veterans face unique challenges and mental health disparities, highlighting the urgent need for gender-sensitive care and support systems.

New research reveals hyperbaric oxygen therapy as a promising treatment for chronic PTSD, enhancing brain function and providing lasting symptom relief.

This Veterans Day, explore the lasting impact of trauma on veterans and the importance of addressing PTSD in our communities.

Younger veterans face significantly higher PTSD rates due to social challenges.

More than 20 years later, what have we learned about PTSD, resiliency, and trauma?

Hurricane Katrina's legacy highlights the urgent need for trauma-informed mental health care in disaster recovery, addressing PTSD and long-term emotional impacts.

Stay informed on PTSD treatment insights, including complex PTSD recognition, diagnostic nuances, and the link between migraines and trauma.

The FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, citing insufficient efficacy despite some positive trial results.

FDA reviewers raise concerns over Rexulti's efficacy for PTSD, highlighting discordant study results ahead of the advisory committee meeting.

The FDA advisory committee will review brexpiprazole for PTSD treatment, which could offer new hope after years without new options.

A psychiatrist reflects on the recent flooding tragedy in Texas.

Transcend Therapeutic announces breakthrough therapy designation for TSND-201 for treating PTSD.

Researchers analyze single-cell communication in brains of people with PTSD, uncovering genetic variations that could lead to new treatments for this complex disorder.

Augmented reality can transform psychiatric treatment, enhancing exposure therapy for trauma and anxiety by simulating real-world environments and interactions.

Effective diagnosis and treatment of comorbid disorders in patients with bipolar enhance care and lead to more optimal mental health outcomes.

Check out the pipeline updates from April!

Transneural Therapeutics launches innovative neuroplastogens to revolutionize treatment for neuropsychiatric diseases, promising safer, effective alternatives to psychedelics.

Although diagnostic criteria for a depressive episode are the same for unipolar major depression and bipolar depression, these episodes differ in their natural history.

How do psychiatrists and mental health professionals respond when faced with disaster? One psychiatrist shares his story.